Genmab — April 2026
-
EPCORE
DLBCL-4 fully recruited https://clinicaltrials.gov/study/NCT06508658?tab=history&a=18&b=19#version-content-panel -
"Genmab nærmer sig vigtige begivenheder - Jefferies finder "overdrevne bekymringer" i markedet
Investorerne forbinder kommende resultater for lymfekræftmidlet Epkinly med en risiko, som den amerikanske storbank Jefferies ikke finder grund til." MedWatch 12:54 Ingen Paywall https://medwatch.dk/brancher/Medicinal___Biotek/article19181589.ece -
The Role of LGR5 in Epithelial Cancer https://www.hematologyandoncology.net/archives/march-april-2026/the-role-of-lgr5-in-epithelial-cancer/
-
Genmab: Multiple Binaries Could Alter The Thesis https://seekingalpha.com/article/4889570-genmab-multiple-binaries-could-alter-thesis
-
Lesions in Radiated/Non-Radiated Fields Achieve Similar Responses with Tisotumab Vedotin in Cervical Cancer https://www.cancernetwork.com/view/lesions-in-radiated-non-radiated-fields-achieve-similar-responses-with-tisotumab-vedotin-in-cervical-cancer?utm_content=375412874&utm_medium=social&utm_source=twitter&hss_channel=tw-22195223
-
Første kvartal: Viser danske selskaber sig kriseturbulente på et uroligt bagtæppe?
De danske regnskaber for C25-selskaberne starter i denne uge. Danske aktier har været
under kurspres de seneste kvartaler og år. Viser resultaterne sig nu mere økonomisk
resistente end den negative aktiekursudvikling lader forstå? https://proinvestor.com/boards/131937 -
Genmab Presents the Safety and Tolerability of Rinatabart Sesutecan (Rina-S
) in Combination with Bevacizumab in Advanced Ovarian Cancer https://proinvestor.com/investornyt/1431279/genmab-presents-the-safety-and-tolerability-of-rinatabart-sesutecan-rina-s-in-combination-with-bevacizumab-in-advanced-ovarian-cancer -
Fandt denne på X, det virker ret overbevisende ?https://www.oncnursingnews.com/view/how-does-rina-s-work-in-patients-with-pretreated-endometrial-cancer-
-
Tisotumab Vedotin With Carboplatin/Pembrolizumab ± Bevacizumab Shows Activity in Cervical Cancer https://www.onclive.com/view/tisotumab-vedotin-with-carboplatin-pembrolizumab-bevacizumab-shows-activity-in-cervical-cancer
-
Genmab (+0,3%, 1795,50) kan få opmærksomhed, når den amerikanske samarbejdspartner og medicinalkoncern Johnson & Johnson kommer med regnskab for første kvartal. Af særlig dansk interesse er information om lægemidlet Darzalex. Genmab modtager royalties for salget af knoglemarvskræftmidlet Darzalex, som markedsføres af Johnson & Johnson.
-
Jyske Bank opgraderer Genmab til Køb fra Hold, siger en længere periode med modvind for virksomheden repræsenterer en god købsmulighed.
De kommende resultater forventes ikke at bringe nogen større nyheder. På den anden side er aktien faldet næsten 20% siden dens seneste top i januar efter makroøkonomiske modvinde og skuffende nyheder om Epkinly.
Med udsigten til en begivenhedsrig anden halvdel af året er det derfor et godt tidspunkt at gå ind i aktien, siger Jyske Bank.
-
Johnson & Johnson reports Q1 2026 results, raises 2026 outlook https://www.jnj.com/media-center/press-releases/johnson-johnson-reports-q1-2026-results-raises-2026-outlook
-
Genmab Announces Net Sales of DARZALEX
(daratumumab) for First Quarter of 2026 https://proinvestor.com/investornyt/1431617/genmab-announces-net-sales-of-darzalex-daratumumab-for-first-quarter-of-2026
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind